

Are the National Comprehensive Cancer Network (NCCN) guidelines regarding use of immunotherapy for Stage III Non small cell lung cancer (NSCLC) in a community setting being followed?



Swe Swe Hlaing MD, Rachele Lanciano MD, John Lamond MD, Benjamin Jacobs MD, Stephen Shore MD, Joseph Tropea DO

INTRODUCTION


- Since the publication of the Pacific Trial December 2018, NCCN guidelines have included one year of Imfinzi following chemotherapy and concurrent radiation for stage III NSCLC. Findings of this trial included a reduction in the risk of death of 32% with immunotherapy vs. placebo following chemotherapy and radiation.
- It is not known if this trial has been endorsed in the community setting.
- We performed a retrospective review of patients with stage III lung cancer who completed chemotherapy and concurrent radiation who were eligible for immunotherapy as per the Pacific trial.
- The goal of the current review is to analyze the use and duration of immunotherapy for patients treated in our American College of Surgeons integrated network cancer program.

METHODOLOGY

- Study type: Retrospective study
- Inclusion Criteria: Stage III NSCLC treated with Chemotherapy and Radiation between 2019 to 2021.
- Exclusion Criteria: those who received Keytruda upfront, palliative, incomplete or no radiation delivered, radiation therapy given alone
- Primary Outcomes: percentage of patients receiving Immunotherapy and duration.
- Secondary Outcomes: reasons for not receiving Imfinzi & not completing Imfinzi for one year

RESULTS

- Total Sample Size: 36 patients obtained from Tumor Registry
- Excluded patients size: 16
- Final Sample Size: 20 patients received concurrent chemotherapy & radiation therapy (60 Gy over 6 weeks) possibly eligible for Imfinzi
- Mean age: 70 (range 50-92 years old)
- Pathology: Adenocarcinoma (n=10), squamous cell carcinoma (n=8) and NSCLC NOS (n=2)
- Stage: IIIA (n=10), Stage IIIB (n=7), Stage IIIC (n=3)
- Received Imfinzi: 85% (17/20 pts)
- Reason for not receiving Imfinzi: radiation pneumonitis (n=1), brain metastasis(n=1) and 1 patient was lost to follow-up
- % pts received 1 year Imfinzi: 35% (6/17) with 2 pts receiving Imfinzi at last follow-up.
- The causes of incomplete Immunotherapy are as follows.



CONCLUSION

- Eighty five percent of patients in our study received Immunotherapy after concurrent chemoradiation per Pacific Trial and NCCN guidelines.
- Thirty five to forty seven percent of those who received Imfinzi completed one year (since two patients continue Imfinzi at last FU).
- The causes of incomplete 12 month course of Imfinzi were primarily due to pulmonary dysfunction, possibly due to treatment.
- This study documents good compliance with NCCN guidelines in our community cancer program.

REFERENCES

- Overall Survival with Durvalumab after chemoradiotherapy in Stage III NSCLC, DOI: 10.1056/NEJMoa1809697
- NCCN guidelines for Stage III NSCLC